

Lack of WASp Unveils Intrinsic Platelet Defects Sustaining Inflammation and Autoimmunity

Authors

Lucia Sereni¹, Maria Carmina Castiello¹, Achille Anselmo², Francesco Marangoni³, Dario Di Silvestre⁴, Sara Motta⁴, Donato Inverso¹, Roberto Aiolfi¹, Elena Draghici¹, Adrian J. Thrasher⁵, Silvia Giliani⁶, Alessandro Aiuti¹, Matteo Iannaccone¹, Pierluigi Mauri⁴, Luigi D. Notarangelo⁷, Marita Bosticardo¹, Anna Villa¹

¹San Raffaele Hospital, Milano, Italy, ²Humanitas Hospital, Milano, Italy, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴National Research Council (ITB-CNR), Milano, Italy, ⁵Institute of Child Health, University College London, London, United Kingdom, ⁶Institute of Molecular Medicine "A. Nocivelli", University Hospital "Spedali Civili", Brescia, Italy, ⁷Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

Abstract

Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency characterized by thrombocytopenia, eczema, high susceptibility to develop autoimmune manifestations and malignancies. Although thrombocytopenia is one of the main causes of death, the pathogenesis of platelet (PLT) defect is poorly understood. Here, we evaluated the role of WAS protein (WASp) in PLTs in a new conditional mouse model (CoWas) lacking WASp only in the megakaryocytic (MK) lineage. We observed an increased number of MKs and their progenitors both in CoWas mice and complete *Was*^{-/-} mice (WKO), as well as normal *in vitro* PLT production by *Was*^{-/-} MKs. Upon *in vivo* depletion of PLTs, WKO and CoWas mice are able to restore PLT count with kinetics comparable to wild-type (WT) mice, suggesting no defect in thrombopoiesis. Of note, WASp-deficient PLTs both in WKO and CoWas mice have a shorter half-life and hyper-activated status before and after ADP stimulation and are more prone to apoptosis. We also found that WKO and CoWas mice develop anti-PLT autoantibodies against *Was*^{-/-} PLTs in line with different proteomic profile. *Was*^{-/-} PLTs show decreased metabolic activity, increased ubiquitination pathways and Immunoglobulin content. Moreover, *Was*^{-/-} PLTs release higher amount of soluble CD40L and are able to induce B-cells activation *in vitro* culture. Finally, WAS patients show increased CD62P and PAC1 expression at steady state and higher sCD40L plasma levels. The activation profile of human PLTs improves after LV-gene therapy treatment, in all the patients, especially in those with a follow up longer than two years.